Sofosbuvir plus Ribavirin is effective for HCV elimination in people living with HIV from rural area of China
Abstract People living with HIV (PLWH) bear higher prevalence of HCV coinfection. An accessible directly acting antivirals regimen with less drug–drug interaction with antiretroviral therapy (ART) is urgently needed in source limited regions. We aimed to assess the efficacy and safety of SOF + RBV f...
Main Authors: | Liyu Chen, Lingyao Du, Shuang Kang, Fanghua Ma, Changmin Li, Min He, Lang Bai, Hong Tang |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-05-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-90706-5 |
Similar Items
-
Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin
by: Tatsuo Kanda, et al.
Published: (2017-05-01) -
Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study
by: Rodolfo Sacco, et al.
Published: (2020-12-01) -
The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin
by: K.S. Abdelkawy, et al.
Published: (2020-01-01) -
Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan
by: Chen-Hua Liu, et al.
Published: (2020-12-01) -
Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection
by: Cody Orr, et al.
Published: (2020-12-01)